Perioperative genomic profiles using structure-specific oligonucleotide probes

Clinical Medicine and Research

Volumn 7, Issue 3, 2009, Pages 69-84

  Hogan, Kirk J ^a   Burmester, James K ^b   Caldwell, Michael D ^b   Hogan, Quinn H ^c   Coursin, Douglas B ^a   Green, Dawn N ^a,d   Selzer, Rebecca M R ^a,d   Broderick, Thomas P ^a   Rusy, Deborah A ^a   Poroli, Mark ^c   Lutz, Anna L ^e   Sanders, Allison M ^e   Oldenburg, Mary C ^e   Koelbl, James A ^e   De Arruda Indig, Monika ^e,f   Halsey, Jennifer L ^a,g   Day, Stephen P ^e   Domanico, Michael J ^e  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b MARSHFIELD CLINIC   (United States)

^c CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Roche NimbleGen Inc   (United States)

^e Third Wave Technologies Inc   (United States)

^f BLOOD RESEARCH INSTITUTE   (United States)

^g Aurora West Allis Medical Center   (United States)

Author keywords

Genetic polymorphisms; Genetic predisposition testing; Genetic susceptibility; Genetic variation; Molecular diagnostic techniques; Oligonucleotide probes; Perioperative care; Perioperative complications; Pharmacogenetics

Indexed keywords

6 PHOSPHOFRUCTO 2 KINASE; ABC TRANSPORTER; APOLIPOPROTEIN E; BETA 2 ADRENERGIC RECEPTOR; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; CHEMOKINE RECEPTOR CCR5; CHOLINESTERASE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DIPEPTIDYL CARBOXYPEPTIDASE; DNA; FRUCTOSE 2,6 BISPHOSPHATASE; HEMOGLOBIN BETA CHAIN; LYMPHOTOXIN; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MYOSIN HEAVY CHAIN; N ACETYLGALACTOSAMINYLTRANSFERASE; PROTEIN SERINE THREONINE KINASE; PROTHROMBIN; THIOPURINE METHYLTRANSFERASE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD GROUP ABO SYSTEM; CONTROLLED STUDY; FAMILY HISTORY; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; LABORATORY TEST; MAJOR CLINICAL STUDY; OLIGONUCLEOTIDE PROBE; PERIOPERATIVE PERIOD; POLYMERASE CHAIN REACTION; PREOPERATIVE EVALUATION; SURGICAL PATIENT; UNITED STATES; WILD TYPE;

ALLELES; ANESTHESIA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOMICS; GENOTYPE; HOMOZYGOTE; HUMANS; MALE; MODELS, BIOLOGICAL; MOLECULAR DIAGNOSTIC TECHNIQUES; OLIGONUCLEOTIDES; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PREOPERATIVE PERIOD;

EID: 70449340661     PISSN: 15394182     EISSN: None     Source Type: Journal    
DOI: 10.3121/cmr.2009.837     Document Type: Article

References (84)

1. th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006. 133-148.
2. Yu SF, Wu LH, Zheng SS. Genetic factors for individual administration of immunosuppressants in organ transplantation. Hepatobiliary Pancreat Dis Int 2006;5:337-344.
3. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 2003;4:397-410. (Pubitemid 36857176)
4. Babaoglu MO, Bayar B, Aynacioglu AS, Kerb R, Abali H, Celik I, Bozkurt A. Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. Clin Pharmacol Ther 2005;78:619-626. (Pubitemid 41773637)
5. Gätke MR, Ostergaard D, Bundgaard JR, Varin F, Viby-Mogensen J. Response to mivacurium in a patient compound heterozygous for a novel and a known silent mutation in the butyrylcholinesterase gene. Anesthesiology 2001;95:600-606.
6. Kalow W, Grant DM. Pharmacogenetics. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 8th ed. New York, NY: McGaw-Hill; 2001. 225-255.
7. Barta C, Sasvari-Szekely M, Devai A, Kovacs E, Staub M, Enyedi P. Analysis of mutations in the plasma cholinesterase gene of patients with a history of prolonged neuromuscular block during anesthesia. Mol Genet Metab 2001;74:484-488. (Pubitemid 34084657)
8. McNamara DM, Holubkov R, Postava L, Janosko K, MacGowan GA, Mathier M, Murali S, Feldman AM, London B. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol 2004;44:2019-2026. (Pubitemid 39473288)
9. Lasocki S, Iglarz M, Seince PF, Vuillaumier-Barrot S, Vicaut E, Henrion D, Levy B, Desmonts JM, Philip I, Bénessiano J. Involvement of renin-angiotensin system in pressure-flow relationship: role of angiotensin-converting enzyme gene polymorphism. Anesthesiology 2002;96:271-275. (Pubitemid 34121732)
10. Völzke H, Engel J, Kleine V, Schwahn C, Dahm JB, Eckel L, Rettig R. Angiotensin I-converting enzyme insertion/deletion polymorphism and cardiac mortality and morbidity after coronary artery bypass graft surgery. Chest 2002;122:31-36. (Pubitemid 34754139)
11. Yende S, Quasney MW, Tolley EA, Wunderink RG. Clinical relevance of angiotensin-converting enzyme gene polymorphisms to predict risk of mechanical ventilation after coronary artery bypass graft surgery. Crit Care Med 2004;32:922-927. (Pubitemid 38471510)
12. Hillman MA, Wilke RA, Yale SH, Vidaillet HJ, Caldwell MD, Glurich I, Berg RL, Schmelzer J, Burmester JK. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res 2005;3:137-145.
13. Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005;77:1-16. (Pubitemid 40089477)
14. Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, Gaston KL, Waddell CD, Chirico MJ, Johnson JA. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 2006;79:291-302.
15. Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, Bentley D, McGinnis R, Deloukas P. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 2007;121:23-34. (Pubitemid 46421137)
16. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, Stein CM. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008;358:999-1008. (Pubitemid 351347099)
17. Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 2006;44:297-302. (Pubitemid 44043771)
18. Inomata S, Nagashima A, Itagaki F, Homma M, Nishimura M, Osaka Y, Okuyama K, Tanaka E, Nakamura T, Kohda Y, Naito S, Miyabe M, Toyooka H. CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin Pharmacol Ther 2005;78:647-655. (Pubitemid 41773640)
19. Caraco Y, Sheller J, Wood AJ. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. J Pharmacol Exp Ther 1996:278:1165-1174. (Pubitemid 27166966)
20. Janicki PK, Schuler HG, Jarzembowski TM, Rossi M 2nd. Prevention of postoperative nausea and vomiting with granisetron and dolasetron in relation to CYP2D6 genotype. Anesth Analg 2006;102:1127-1133.
21. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J. Codeine intoxication associated with ultrarapid CYP2D6 metabolism (erratum appears in: N Engl J Med 2005;352:638.). N Engl J Med 2004;351:2827-2831.
22. Stamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin Pharmacol Ther 2007;82:41-47. (Pubitemid 46944194)
23. Candiotti KA, Birnbach DJ, Lubarsky DA, Nhuch F, Kamat A, Koch WH, Nikoloff M, Wu L, Andrews D. The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? Anesthesiology 2005;102:543-549.
24. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, Thummel KE. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002;62:162-172.
25. Tsuchiya N, Satoh S, Tada H, Li Z, Ohyama C, Sato K, Suzuki T, Habuchi T, Kato T. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004;78:1182-1187.
26. Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, Shen DD, Thummel KE. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 2006;34:836-847.
27. Park JY, Kim KA, Park PW, Lee OJ, Kang DK, Shon JH, Liu KH, Shin JG. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. Clin Pharmacol Ther 2006;79:590-599.
28. Kim NS, Lee IO, Lee MK, Lim SH, Choi YS, Kong MH. The effects of beta2 adrenoceptor gene polymorphisms on pressor response during laryngoscopy and tracheal intubation. Anaesthesia 2002;57:227-232.
29. Kaymak C, Kocaba? NA, Durmaz E, Oztuna D. beta2 adrenoceptor (ADRB2) pharmacogenetics and cardiovascular phenotypes during laryngoscopy and tracheal intubation. Int J Toxicol 2006;25:443-449. (Pubitemid 44885099)
30. Hawkins GA, Tantisira K, Meyers DA, Ampleford EJ, Moore WC, Klanderman B, Liggett SB, Peters SP, Weiss ST, Bleecker ER. Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study. Am J Respir Crit Care Med 2006;174:1101-1109. (Pubitemid 44772080)
31. Schaeffeler E, Fischer C, Brockmeier D, Wernet D, Moerike K, Eichelbaum M, Zanger UM, Schwab M. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004;14:407-417. (Pubitemid 38971231)
32. Doggen CJ, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998;97:1037-1041.
33. Welsby IJ, Podgoreanu MV, Phillips-Bute B, Mathew JP, Smith PK, Newman MF, Schwinn DA, Stafford-Smith M; Perioperative Genetics and Safety Outcomes Study (PEGASUS) Investigative Team. Genetic factors contribute to bleeding after cardiac surgery. J Thromb Haemost 2005;3:1206-1212. (Pubitemid 41725243)
34. Donahue BS, Gailani D, Higgins MS, Drinkwater DC, George AL Jr. Factor V Leiden protects against blood loss and transfusion after cardiac surgery. Circulation 2003;107:1003-1008. (Pubitemid 36258724)
35. Donahue BS. Factor V Leiden and perioperative risk. Anesth Analg 2004;98:1623-1634.
36. Edmonds MJ, Crichton TJ, Runciman WB, Pradhan M. Evidence-based risk factors for postoperative deep vein thrombosis. ANZ J Surg 2004;74:1082-1097. (Pubitemid 40006994)
37. Campo G, Valgimigli M, Ferraresi P, Malagutti P, Baroni M, Arcozzi C, Gemmati D, Percoco G, Parrinello G, Ferrari R, Bernardi F. Tissue factor and coagulation factor VII levels during acute myocardial infarction: association with genotype and adverse events. Arterioscler Thromb Vasc Biol 2006;26:2800-2806. (Pubitemid 44777300)
38. Botto N, Andreassi MG, Rizza A, Berti S, Bevilacqua S, Federici C, Palmieri C, Glauber M, Biagini A. C677T polymorphism of the methylenetetrahydrofolate reductase gene is a risk factor of adverse events after coronary revascularization. Int J Cardiol 2004;96:341-345. (Pubitemid 39099494)
39. Selzer RR, Rosenblatt DS, Laxova R, Hogan K. Adverse effect of nitrous oxide in a child with 5,10-methylenetetrahydrofolate reductase deficiency. N Engl J Med 2003;349:45-50. (Pubitemid 36765102)
40. Stuber F, Petersen M, Bokelmann F, Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 1996;24:381-384. (Pubitemid 26097828)
41. Shaw AD, Vaporciyan AA, Wu X, King TM, Spitz MR, Putnam JB, Dickey BF. Inflammatory gene polymorphisms influence risk of postoperative morbidity after lung resection. Ann Thorac Surg 2005;79:1704-1710. (Pubitemid 40614592)
42. Holweg CT, Weimar W, Uitterlinden AG, Baan CC. Clinical impact of cytokine gene polymorphisms in heart and lung transplantation. J Heart Lung Transplant 2004;23:1017-1026. (Pubitemid 39345644)
43. Bittar MN, Carey JA, Barnard JB, Pravica V, Deiraniya AK, Yonan N, Hutchinson IV. Tumor necrosis factor alpha influences the inflammatory response after coronary surgery. Ann Thorac Surg 2006;81:132-137. (Pubitemid 41815386)
44. Khalil AA, Hall JC, Aziz FA, Price P. Tumour necrosis factor: implications for surgical patients. ANZ J Surg 2006;76:1010-1016. (Pubitemid 44581492)
45. Tomasdottir H, Hjartarson H, Ricksten A, Wasslavik C, Bengtsson A, Ricksten SE. Tumor necrosis factor gene polymorphism is associated with enhanced systemic inflammatory response and increased cardiopulmonary morbidity after cardiac surgery. Anesth Analg 2003; 97:944-949. (Pubitemid 37158670)
46. Ryan R, Thornton J, Duggan E, McGovern E, O'Dwyer MJ, Ryan AW, Kelleher D, McManus R, Ryan T. Gene polymorphism and requirement for vasopressor infusion after cardiac surgery. Ann Thorac Surg 2006;82:895-901. (Pubitemid 44246710)
47. Abdi R, Tran TB, Sahagun-Ruiz A, Murphy PM, Brenner BM, Milford EL, McDermott DH. Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol 2002;13:754-758. (Pubitemid 34183942)
48. Nischalke HD, Nattermann J, Lichterfeld M, Woitas RP, Rockstroh JK, Sauerbruch T, Spengler U. Rapid determination of the Delta32 deletion in the human CC-chemokine receptor 5 (CCR5) gene without DNA extraction by lightcycler real-time polymerase chain reaction. AIDS Res Hum Retroviruses 2004;20:750-754. (Pubitemid 39037506)
49. Lelis RG, Krieger JE, Pereira AC, Schmidt AP, Carmona MJ, Oliveira SA, Auler JO Jr. Apolipoprotein E4 genotype increases the risk of postoperative cognitive dysfunction in patients undergoing coronary artery bypass graft surgery. J Cardiovasc Surg (Torino) 2006;47:451-456. (Pubitemid 44463386)
50. MacKensen GB, Swaminathan M, Ti LK, Grocott HP, Phillips-Bute BG, Mathew JP, Newman MF, Milano CA, Stafford-Smith M; Perioperative Outcomes Research Group; Cardiothoracic Anesthesiology Research Endeavors (C.A.R.E.) Investigators of the Duke Heart Center. Preliminary report on the interaction of apolipoprotein E polymorphism with aortic atherosclerosis and acute nephropathy after CABG. Ann Thorac Surg 2004;78:520-526.
51. Stafford-Smith M, Podgoreanu M, Swaminathan M, Phillips-Bute B, Mathew JP, Hauser EH, Winn MP, Milano C, Nielsen DM, Smith M, Morris R, Newman MF, Schwinn DA; Perioperative Genetics and Safety Outcomes Study (PEGASUS) Investigative Team. Association of genetic polymorphisms with risk of renal injury after coronary bypass graft surgery. Am J Kidney Dis 2005;45:519-530. (Pubitemid 40341331)
52. Grocott HP, Newman MF, El-Moalem H, Bainbridge D, Butler A, Laskowitz DT. Apolipoprotein E genotype differentially influences the proinflammatory and anti-inflammatory response to cardiopulmonary bypass. J Thorac Cardiovasc Surg 2001;122:622-623. (Pubitemid 32843971)
53. Heyer EJ, Wilson DA, Sahlein DH, Mocco J, Williams SC, Sciacca R, Rampersad A, Komotar RJ, Zurica J, Benvenisty A, Quest DO, Todd G, Solomon RA, Connolly ES Jr. APOE-epsilon4 predisposes to cognitive dysfunction following uncomplicated carotid endarterectomy. Neurology 2005;65:1759-1763. (Pubitemid 43754407)
54. Mason P. Sickle cell disease in the perioperative setting. J Perioper Pract 2006;16:443-446.
55. Poliac LC, Barron ME, Maron BJ. Hypertrophic cardiomyopathy. Anesthesiology 2006;104:183-192.
56. Westhoff CM. Molecular testing for transfusion medicine. Curr Opin Hematol 2006;13:471-475.
57. Izrailtyan I, Podgoreanu M, Phillips-Bute B, Stafford-Smith M, Milano C, Schwinn D, Newman M, Matthew J. Gender related differences in genetic polymorphisms and major adverse outcomes following cardiac surgery. Anesth Analg 2005;100:SCA25.
58. Schiebel K, Mertz A, Winkelmann M, Gläser B, Schempp W, Rappold G. FISH localization of the human Y-homolog of protein kinase PRKX (PRKY) to Yp11.2 and two pseudogenes to 15q26 and Xq12-q13. Cytogenet. Cell Genet 1997;76:49-52.
59. Batra RS, Hatchwell E, Rider S, Brown R, Brown GK, Craig IW. Localization of human liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB1) within a YAC contig in Xp11.21. Genomics 1997;40:358-361.
60. Olivier M. The Invader assay for SNP genotyping. Mutat Res 2005;573:103-110.
61. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70:189-199.
62. Boeck AT, Fry DL, Sastre A, Lockridge O. Naturally occurring mutation, Asp70his, in human butyrylcholinesterase. Ann Clin Biochem 2002;39(Pt 2):154-156.
63. Zee RY, Cook NR, Cheng S, Reynolds R, Erlich HA, Lindpaintner K, Ridker PM. Polymorphism in the P-selectin and interleukin-4 genes as determinants of stroke: a population-based, prospective genetic analysis. Hum Mol Genet 2004;13:389-396.
64. Moridani M, Fu L, Selby R, Yun F, Sukovic T, Wong B, Cole DE. Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort. Clin Biochem 2006;39:606-612.
65. Blaisdell J, Mohrenweiser H, Jackson J, Ferguson S, Coulter S, Chanas B, Xi T, Ghanayem B, Goldstein JA. Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics 2002;12:703-711.
66. Chou WH, Yan FX, Robbins-Weilert DK, Ryder TB, Liu WW, Perbost C, Fairchild M, de Leon J, Koch WH, Wedlund PJ. Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem 2003;49:542-551.
67. Marez D, Legrand M, Sabbagh N, Guidice JM, Spire C, Lafitte JJ, Meyer UA, Broly F. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997;7:193-202.
68. Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, Zhang J, Schuetz EG. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002;12:121-132. (Pubitemid 34298916)
69. Floyd MD, Gervasini G, Masica AL, Mayo G, George AL Jr, Bhat K, Kim RB, Wilkinson GR. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 2003;13:595-606.
70. Otterness D, Szumlanski C, Lennard L, Klemetsdal B, Aarbakke J, Park-Hah JO, Iven H, Schmiegelow K, Branum E, O'Brien J, Weinshilboum R. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997;62:60-73. (Pubitemid 27327100)
71. Yan L, Zhang S, Eiff B, Szumlanski CL, Powers M, O'Brien JF, Weinshilboum RM. Thiopurine methyltransferase polymorphic tandem repeat: genotype-phenotype correlation analysis. Clin Pharmacol Ther 2000;68:210-219. (Pubitemid 30659176)
72. Rady PL, Szucs S, Grady J, Hudnall SD, Kellner LH, Nitowsky H, Tyring SK, Matalon RK. Genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) in ethnic populations in Texas; a report of a novel MTHFR polymorphic site, G1793A. Am J Med Genet 2002;107:162-168. (Pubitemid 34038599)
73. Lorey FW, Arnopp J, Cunningham GC. Distribution of hemoglobinopathy variants by ethnicity in a multiethnic state. Genet Epidemiol 1996;13:501-512. (Pubitemid 26359326)
74. Ackerman MJ, VanDriest SL, Ommen SR, Will ML, Nishimura RA, Tajik AJ, Gersh BJ. Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. J Am Coll Cardiol 2002;39:2042-2048. (Pubitemid 34628288)
75. Yip SP. Single-tube multiplex PCR-SSCP analysis distinguishes 7 common ABO alleles and readily identifies new alleles. Blood 2000;95:1487-1492.
76. Pompanon F, Bonin A, Bellemain E, Taberlet P. Genotyping errors: causes, consequences and solutions. Nat Rev Genet 2005;6:847-859.
77. Johnson MA, Yoshitomi MJ, Richards CS. A comparative study of five technologically diverse CFTR testing platforms. J Mol Diagn 2007;9:401-407.
78. Weiser TG, Regenbogen SE, Thompson KD, Haynes AB, Lipsitz SR, Berry WR, Gawande AA. An estimation of the global volume of surgery: a modelling strategy based on available data. Lancet 2008;372:139-144.
79. Lagasse RS. Anesthesiology safety: model or myth? A review of the published literature and analysis of current original data. Anesthesiology 2002;97:1609-1617.
80. Bothner U, Georgieff M, Schwilk B. Building a large-scale perioperative anaesthesia outcome-tracking database: methodology, implementation, and experiences from one provider within the German quality project. Br J Anaesth 2000;85:271-280. (Pubitemid 30601620)
81. Cohen MM, Duncan PG, Pope WD, Biehl D, Tweed WA, MacWilliam L, Merchant RN. The Canadian four-centre study of anaesthetic outcomes: II. Can outcomes be used to assess the quality of anaesthesia care? Can J Anaesth 1992;39:430-439.
82. Forrest JB, Rehder K, Cahalan MK, Goldsmith CH. Multicenter study of general anesthesia. III. Predictors of severe perioperative adverse outcomes. Anesthesiology 1992;76:3-15.
83. Hogan K. Pharmacogenetics and pharmacogenomics of drug action. In: Anesthetic pharmacology; Physiologic principles and clinical practice. Evers AS, Maze M, eds. 2nd ed. St. Louis, MO: Harcourt, Inc.; 2004. 79-90.
84. Sigurdsson GH, McAteer E. Morbidity and mortality associated with anaesthesia. Acta Anaesthesiol Scand 1996;40:1057-1063.